Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 Combination Therapy in Advanced Lung Cancer
CTR20255022Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JS212 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd. Started Jan 2026; status: active.
02
Drugs
JS212
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20255022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255022.